Skip to main content

13.07.2016 | Onkologie | Online-Artikel

Locally advanced NSCLC: oral vinorelbine shows better safety profile than etoposide

The randomised, multicentre, open-label, phase II RENO trial was conducted with the objective of establishing a standard chemotherapy regimen in the setting of chemo-radiotherapy of locally advanced NSCLC. A total of 134 patients with inoperable stage III NSCLC received either oral vinorelbine plus cisplatin or etoposide plus cisplatin.